

FOR IMMEDIATE RELEASE

Alfa Wassermann Diagnostic Technologies Introduces COVID-19 Reagent Panel

For Follow-Up Monitoring of COVID-19 Patients in the Physician Office Laboratory

WEST CALDWELL, NJ – May 19, 2020 – Alfa Wassermann Diagnostic Technologies, LLC (AWDT) announced today the introduction of a COVID-19 Reagent Panel for follow-up care of vulnerable COVID-19 patients with underlying health conditions. The attached resource, *Follow-Up Monitoring of COVID-19 Patients in the Physician Office Laboratory*, highlights the importance of monitoring patients with liver, kidney, or cardiovascular conditions as well as those who showed abnormal levels in organ testing after contracting COVID-19. Vulnerable patients in recovery from the virus require continuous monitoring to reduce the risk of increased injury and hospitalization. By monitoring COVID-19 patients, physician office labs will receive the opportunity to help prescribe optimal care and/or applicable therapeutic options under investigation.

Alfa Wassermann Diagnostic Technologies, LLC offers a variety of assays for follow-up monitoring of liver, kidney, and cardiovascular functions for use on the ACE Alera[®] and ACE Axcel[®] Clinical Chemistry Systems. For ordering information, please contact a Business Development Manager at Alfa Wassermann Diagnostic Technologies, LLC.

About Alfa Wassermann Diagnostic Technologies, LLC

Alfa Wassermann Diagnostic Technologies, LLC is a leading provider of medical diagnostic instrumentation and reagents to the physician office, veterinary lab, and biopharmaceutical markets. Alfa Wassermann's diagnostic technology products include the ACE Alera[®], ACE Axcel[®], and Vet Axcel[®] clinical chemistry analyzers that are sold around the world to physicians, veterinarians, research laboratories, and other such medical facilities, including many of the leading pharmaceutical companies, academic institutions, and animal conservatories.

For further information, please contact:

Tanya De Boer

Director of Marketing

800-220-4488 x265

TDeBoer@AlfaWassermannUS.com

www.AlfaWassermannUS.com

###

All trademarks, service marks and company names are the property of their respective owners.

Follow-Up Monitoring of COVID-19 Patients

in the Physician Office Laboratory


Coronavirus Disease (COVID-19)

WHO

Patients with underlying liver, kidney, or cardiovascular conditions as well as those who showed abnormal levels in organ testing after contracting COVID-19 may have had a severe case of the virus and should be monitored more closely.



Up to
53%
of all hospitalized patients
displayed elevated liver
enzymes and impaired
kidney function.⁶



BIOMARKERS OF COVID-19 SEVERITY


- ↑ Alanine Aminotransferase (ALT)^{1,2,5-12}
- ↓ Albumin (ALB)^{1,4-7,10-12}
- ↑ Aspartate Aminotransferase (AST)^{1,2,4-6, 8-11}
- ↑ Creatine Kinase (CK)^{1,3,5,7-9}
- ↑ Creatinine (CREAT)^{1,7,8,10,12}
- ↑ Serum Ferritin (FERITN)^{1,7,11,12}
- ↑ Lactate Dehydrogenase (LDH)¹⁻¹²
- ↑ Total Bilirubin (TBILI)^{1,5,10,12}

WHAT



WHY

Patients in recovery require continuous monitoring to reduce the risk of increased injury such as renal or hepatic dysfunction, to help eliminate the need for hospitalization for asymptomatic or pre-symptomatic patients, and to help prescribe optimal care or applicable therapeutic options under investigation.



ALFA WASSERMANN COVID-19 REAGENT PANEL

Alfa Wassermann offers a variety of assays for follow-up monitoring of liver, kidney, and cardiovascular functions for use on the ACE Axcel[®] and ACE Alera[®] Clinical Chemistry Systems.

Alanine Aminotransferase (ALT)
Albumin (ALB)
Aspartate Aminotransferase (AST)
Creatine Kinase (CK)
Creatinine (CREAT)
Ferritin (FERITN)
Lactate Dehydrogenase (LDH)
Total Bilirubin (TBILI)

Contact your local Business Development Manager for ordering information.

SCIENTIFIC REFERENCES

1. Henry et al. 2020 Apr 10 Clinical Chemistry and Laboratory Medicine. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 PMID: 32286245 DOI: 10.1515/cclm-2020-0369.
2. Ferrari et al. 2020 Apr 16 Clinical Chemistry and Laboratory Medicine. Routine blood tests as a potential diagnostic tool for COVID-19 PMID: 3230176 DOI: 10.1515/cclm-2020-0398.
3. Yuan et al. 2020 Mar 29 Inflammation Research. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients PMID: 32227274 DOI: 10.1007/s00011-020-013242-0.
4. Huang et al. 2020 Feb 15 The Lancet. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China PMID: 31986264 PMCID: PMC7159299 DOI: 10.1016/S0140-6736(20) 30183-5.
5. Chen et al. 2020 Feb 15 The Lancet. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study PMID: 32007143 PMCID: PMC7135076 DOI: 10.1016/S0140-6736(20)30211-7.
6. The Governing Board The American Association for the Study of Liver Diseases, Released: April 7, 2020. CLINICAL INSIGHTS FOR HEPATOLOGY AND LIVER TRANSPLANT PROVIDERS DURING THE COVID-19 PANDEMIC.
7. Zhou et al. 2020 Mar 28 The Lancet. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study PMID 32171076 DOI: 10.1016/S0140-6736(20) 30566-3.
8. Guan et al. 2020 Apr 30 The New England Journal of Medicine. The Clinical Characteristics of Coronavirus Disease 2019 in China PMID: 32109013 PMCID: PMC7092819 DOI: 10.1056/NEJMoa2002032.
9. Holshue et al and The Washington State 2019-nCoV Case Investigation Team 2020 Mar 5 The New England Journal of Medicine Case Reports. First Case of 2019 Novel Coronavirus in the United States PMID: 32004427 PMCID: PMC7092802 DOI: 10.1056/NEJMoa2001191.
10. Wu et al. 2020 Mar 13 JAMA Internal Medicine. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China PMID: 32167524 PMCID: PMC7070509 DOI: 10.1001/jamainternmed.2020.0994.
11. Chen et al. 2020 May 1 The Journal of Clinical Investigation. Clinical and immunological features of severe and moderate coronavirus disease 2019 PMID: 32217835 PMCID: PMC7190990 (available on 2020-08-01) DOI: 10.1172/JCI137244.
12. Wang et al. 2020 Apr 23 The Journal of Clinical Investigation Insight. The laboratory tests and host immunity of COVID-19 patients with different severity of illness PMID: 32324595 DOI: 10.1172/jci.insight.137799.

Business Development Managers

Jodi Buckles
AK, AZ, CA, HI, ID, NV, OR, UT, WA
602-369-1932
jbuckles@alfawassermannus.com

Frank Pollock
DC, FL, GA, MD, NC, SC, VA
803-622-7881
fpollock@alfawassermannus.com

David Christy
AL, AR, FL Panhandle, MS, Northwest GA
201-247-6123
dchristy@alfawassermannus.com

Steve Wilson
CO, Southern IL, IN, KS, KY, MO, OH, TN, WV
270-668-3605
swilson@alfawassermannus.com

John Husted
IA, Northern IL, MI, MN, MT, ND, NE, SD, WI, WY
630-881-9011
jhusted@alfawassermannus.com

Jennifer Yeakley
LA, NM, OK, TX
727-798-8212
jyeakley@alfawassermannus.com

Scott Lavine
CT, DE, MA, ME, NH, NJ, NY, PA, RI, VT
410-370-9638
slavine@alfawassermannus.com

Contact your local Business Development Manager for ordering information.